Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy
Status:
Completed
Trial end date:
2014-05-09
Target enrollment:
Participant gender:
Summary
This study will assess the impact of omalizumab on the quality of life improvement when added
to the standard therapy in refractory patients suffering from chronic spontaneous urticaria
and angioedema.